ResearchMoz presents this most up-to-date research on “Diagnosis And Monitoring Of Non-alcoholic Steatohepatitis (NASH) Biomarkers Global Market Over The Period 2017 – 2024”.
Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). NASH is an advanced form of NAFLD where the liver inflammation occurs owing to fat deposition in liver. The fat accumulation may be induced by genetic abnormalities, metabolic dysfunction, drug induced damages, etc. Untreated and advanced NASH is one of the major reason for liver cirrhosis and sever liver damage such as liver failure. Presently three distinct method are used for diagnosis and monitoring of NASH, those are biopsy derived histopathology, imaging tools like transient elastography (TE), magnetic resonance imaging (MRI), etc., and in vitro diagnostic using biomarkers. As per the World Gastroenterology Organization It is estimated that around 20% to 30% of world population is affected with NAFLD.
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Contract Research Organization(CRO) & Pharmaceutical Industry
- Academic Research Institutes
- Diagnostic Laboratories